Clinical trial
Compassionate Use of Campath-1H in Treating Patients With Refractory…
NCT00021151 · Case Comprehensive Cancer Center, Other · Completed
Key facts
| NCT number | NCT00021151 |
|---|---|
| Title | Compassionate Use of Campath-1H in Treating Patients With Refractory Prolymphocytic Leukemia or Chronic Lymphocytic Leukemia |
| Official title | CAMPATH-1H Compassionate Treatment In Patients With PLL Who Have Failed At Least One Prior Regimen And CLL Patients Who Have Failed Fludarabine Therapy |
| Lead sponsor | Case Comprehensive Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH Genzyme, a Sanofi Company Industry |
| Status | Completed |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Biological |
| Interventions | alemtuzumab |
| Enrollment | 2 |
| Start date | Jan 1, 2000 |
| Primary completion | Apr 1, 2001 |
| Completion | May 1, 2002 |
| First posted | Apr 13, 2004 |
| Last update posted | Jan 9, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: